Ascendis Pharma A/S
ASND evidence brief
What we can confirm
- BioSniper Score:
- 7.5 / 10
- Market Cap:
- $17.33B
- Lead Asset:
- Navepegritide (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for ASND—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ASND
Ascendis Pharma A/S is a Danish biotech company focused on rare endocrine diseases, leveraging its TransCon drug delivery platform to develop and commercialize three approved therapies—SKYTROFA, YORVIPATH, and YUVIWEL—and a pipeline of candidates including navepegritide for achondroplasia.
Key risk: Competition in achondroplasia
BioSniper Score
Based on 4 of 6 signals
Market Cap
$17.33B
Cash Runway
—
Lead Asset
Navepegritide (Phase 2/Phase 3)Next Catalyst
Patent_Expiry · Feb 27, 2033Tracking 3 pipeline candidates · 25 clinical trials · 2 catalysts · 3 FDA decisions for Ascendis Pharma A/S.
Similar companies
Ascendis Pharma A/S is a Danish biotech company focused on rare endocrine diseases, leveraging its TransCon drug delivery platform to develop and commercialize three approved therapies—SKYTROFA, YORVIPATH, and YUVIWEL—and a pipeline of candidates including navepegritide for achondroplasia.
- Total product revenue roughly doubled year-over-year to €315 million in Q2 2026 [news · published 2026-08-21].
- Q2 2026 sales of €339.29 million, net income of €206.97 million, and basic earnings per share of €3.22 [news · published 2026-08-20].
- Three approved TransCon therapies (SKYTROFA, YORVIPATH, YUVIWEL) all contributing meaningful sales in the same quarter for the first time [news · published 2026-08-21].
- Week 52 data from the reACHin trial showed navepegritide provided stabilization or improvement in foramen magnum stenosis alongside linear growth benefits in infants with achondroplasia [news · published 2026-09-10].
- Week 104 data from the pivotal ApproaCH Trial of navepegritide in children with achondroplasia was presented at ISDS 2026 [news · published 2026-08-25].
What works
- Three approved products (SKYTROFA, YORVIPATH, YUVIWEL) are generating growing revenue, with Q2 2026 product revenue roughly doubling year-over-year to €315 million [news · published 2026-08-21].
- Navepegritide (TransCon CNP) has shown positive clinical data in both infants and children with achondroplasia, including foramen magnum stenosis improvement and linear growth benefits [news · published 2026-09-10].
- The company has a strong pipeline with multiple ongoing Phase 3 trials, including a basket trial for lonapegsomatropin in growth failure/short stature conditions [catalyst].
What to weigh
- The company faces competition from BridgeBio, which reported Phase 3 data for achondroplasia and plans FDA filing in 2026 [news · published 2026-02-12].
- Patent expirations for key products are decades away (2033 for navepegritide, 2042 for palopegteriparatide), but eventual loss of exclusivity could impact long-term revenue [catalyst].
- The company's financials show a net income of €206.97 million on sales of €339.29 million in Q2 2026, implying significant operating expenses [news · published 2026-08-20].
From the filings
Quoted directly from source documents.
Total product revenue roughly doubled year-over-year to €315 million in Q2 2026
“Total product revenue roughly doubled from a year earlier to €315 million”
News · August 21, 2026
Q2 2026 sales of €339.29 million, net income of €206.97 million
“The company reported second quarter sales of €339.29 million, with net income of €206.97 million”
News · August 20, 2026
Navepegritide showed stabilization or improvement in foramen magnum stenosis in infants with achondroplasia
“once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis alongside linear growth benefits in infants with achondroplasia aged 0 to under 2 years”
News · September 10, 2026
Week 104 data from the pivotal ApproaCH Trial of navepegritide was presented at ISDS 2026
“oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia”
News · August 25, 2026
Catalyst timeline
- 2033-02-27 · Patent_Expiry · NAVEPEGRITIDE — Patent_Expiry: NDA219164 — Patent expiry for navepegritide; could open the door for generic competition.
- 2042-11-12 · Patent_Expiry · PALOPEGTERIPARATIDE — Patent_Expiry: NDA216490 — Patent expiry for palopegteriparatide; potential loss of exclusivity.
Risks & what to watch (3)›
Key risks
- Competition in achondroplasia — BridgeBio reported Phase 3 data and plans FDA filing in 2026, potentially competing with navepegritide [news · published 2026-02-12].
- Patent expirations — Key patents expire in 2033 (navepegritide) and 2042 (palopegteriparatide), which could eventually allow generic competition [catalyst].
- Operating expense burden — Q2 2026 net income of €206.97M on €339.29M sales implies high operating costs [news · published 2026-08-20].
What to watch
- Regulatory decisions and competitive landscape for navepegritide in achondroplasia, especially relative to BridgeBio's filing plans [news · published 2026-02-12].
- Continued commercial performance of YORVIPATH and YUVIWEL, which drove Q2 2026 revenue growth [news · published 2026-08-14].
- Data from ongoing Phase 3 trials, including the basket trial for lonapegsomatropin and the reACHin infant trial [catalyst].
- Patent expiry timelines for navepegritide (2033) and palopegteriparatide (2042) and any potential impact on long-term revenue [catalyst].
Sources: Catalysts · News · Generated October 13, 2026 · How we verify sources →
Run Ascendis Pharma A/S through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ascendis Pharma A/S facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
2 upcoming, next in ~2328d
9 buys · 1 sell (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 5.5%
- Days to cover
- 2.7
- Shares short
- 2,832,689
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ASND short interestFrequently asked questions
What is the AI investment thesis for Ascendis Pharma A/S?
Ascendis Pharma A/S is a Danish biotech company focused on rare endocrine diseases, leveraging its TransCon drug delivery platform to develop and commercialize three approved therapies—SKYTROFA, YORVIPATH, and YUVIWEL—and a pipeline of candidates including navepegritide for achondroplasia.
What is Ascendis Pharma A/S's lead drug candidate?
Ascendis Pharma A/S's most advanced tracked candidate is Navepegritide (Phase 2/Phase 3) for Achondroplasia.
What is Ascendis Pharma A/S's next catalyst?
Ascendis Pharma A/S's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA219164" — expected February 27, 2033.
Who is the CEO of Ascendis Pharma A/S?
Mr. Jan Moller Mikkelsen is the chief executive officer of Ascendis Pharma A/S (ASND).
Where is Ascendis Pharma A/S headquartered?
Ascendis Pharma A/S (ASND) is headquartered in Hellerup, Denmark.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.